EC Paediatrics

Introduction: Short bowel syndrome (SBS) is a rare disease, however, the awareness of current trends in SBS patients treatment approaches, including the example of pediatric patients management in the Tyumen region of Russia, is of significant scientific and medical interest due to improvement of nursing patient after extensive bowel resections, as well as development of parenteral nutrition opportunities, including home based options.

Basic Provisions: Patients with SBS require a multidisciplinary approach. The traditional tactic for treating such patients includes lifelong parenteral nutrition or intestinal transplantation, as a last resort. Rehabilitation measures for children with SBS should take into account the requirements for correcting malabsorption and rehabilitating nutritional status; relief of diarrhea, prevention and treatment of dysbacteriosis; control and correction of general digestive disorders.

The Discussion of the Results: The experience of management of five children with SBS in the Tyumen region of Russia was evaluated. It was found that the analogue of glucagon-like peptide 2 (GLP-2) - teduglutide - makes it possible to reduce the amount of parenteral nutrition, the time of infusions, as well as to gain a complete transition to enteral autonomy.

Conclusion: The method of treatment with teduglutide is the most promising for patients of this category.

Keywords: Short Bowel Syndrome; Intestinal Failure; Intestinal Adaptation; Parenteral Nutrition; Teduglutide

1. Pironi L., et al. “ESPEN Endorsed Recommendations. Definition and Classification of Intestinal Failure in Adults”. Clinical Nutrition2 (2015): 171-180.
2. Weih S., et al. “Current Practice and Future Perspectives in the Treatment of Short Bowel Syndrome in Children - A Systematic Review”. Langenbeck's Archives of Surgery7 (2012): 1043-1051.
3. Sulkowski JP and Minneci PC. “Management of Short Bowel Syndrome”. Pathophysiology1 (2014): 111-118.
4. McGee DC and Gould MK. “Preventing Complications of Central Venous Catheterization”. The New England Journal of Medicine12 (2003): 1123-1133.
5. Revestive (Teduglutide) Summary of Product Characteristics. Shire Pharmaceuticals Ireland Limited (2019).
6. Norsa L., et al. “The Colon as an Energy Salvage Organ for Children with Short Bowel Syndrome”. The American Journal of Clinical Nutrition4 (2019): 1112-1118.
7. Kocoshis SA., et al. “Safety and Efficacy of Teduglutide in Pediatric Patients with Intestinal Failure Due to Short Bowel Syndrome: A 24-Week, Phase III Study”. Journal of Parenteral and Enteral Nutrition4 (2019): 621-631.
8. Sosnovskaya EV. “Modern pharmacotherapy options for patients with short intestine syndrome. Bulletin of SURSU”. Medicine50 (2021): 26-30.
9. Averyanova YuV., et al. “Clinical Guidelines of the Northwestern Association of Parenteral and Enteral Nutrition, Interregional Association for Emergency Surgery, the Russian Gastroenterological Association, the Union of Rehabilitologists of Russia and the Russian Transplantation Society for the Diagnosis and Treatment of Short Intestine Syndrome with Intestinal Insufficiency in Adults”. Russian Journal of Gastroenterology, Hepatology, Coloproctology1 (2022): 60-103.